Overview

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
Phase:
Phase 1
Details
Lead Sponsor:
ChemGenex Pharmaceuticals
Treatments:
Harringtonines
Homoharringtonine